Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine for AML Consolidation and Maintenance
NCT01873495Phase 2Terminated
- Sponsor
- Emory University
- Start
- May 2013
- Primary completion
- Jul 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of homoharringtonine in acute myeloid leukemia (AML), sponsored by Emory University. Primary endpoints: Disease Status Assessment Prior to Each Consolidation Cycle at 14 days, Assessment of Disease Status at 1 month and 2 more. Started May 2013; status: terminated.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01873495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01873495.